Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Sponsor: Columbia University
Summary
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease. Patients will receive a chemotherapy regimen with busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a family-related or cord-blood matched donor.
Official title: Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia
Key Details
Gender
All
Age Range
1 Month - 30 Years
Study Type
INTERVENTIONAL
Enrollment
53
Start Date
2004-09
Completion Date
2025-02
Last Updated
2024-06-13
Healthy Volunteers
No
Conditions
Interventions
Busulfan
Busulfan 4 mg/kg/d x 4d
Fludarabine
Fludarabine 30 mg/m2/d x 6d
Alemtuzumab
Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
Allogeneic stem cell transplant
Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
Locations (1)
Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University
New York, New York, United States